GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort NeuroTech Ltd (HKSE:02172) » Definitions » ROCE %

MicroPort NeuroTech (HKSE:02172) ROCE % : 11.35% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is MicroPort NeuroTech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MicroPort NeuroTech's annualized ROCE % for the quarter that ended in Dec. 2023 was 11.35%.


MicroPort NeuroTech ROCE % Historical Data

The historical data trend for MicroPort NeuroTech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort NeuroTech ROCE % Chart

MicroPort NeuroTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
29.51 12.93 8.40 6.66 9.98

MicroPort NeuroTech Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROCE % Get a 7-Day Free Trial 2.74 0.11 13.33 8.62 11.35

MicroPort NeuroTech ROCE % Calculation

MicroPort NeuroTech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=181.032/( ( (2029.071 - 272.255) + (2144.508 - 272.623) )/ 2 )
=181.032/( (1756.816+1871.885)/ 2 )
=181.032/1814.3505
=9.98 %

MicroPort NeuroTech's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=208.56/( ( (2071.042 - 266.618) + (2144.508 - 272.623) )/ 2 )
=208.56/( ( 1804.424 + 1871.885 )/ 2 )
=208.56/1838.1545
=11.35 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MicroPort NeuroTech  (HKSE:02172) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


MicroPort NeuroTech ROCE % Related Terms

Thank you for viewing the detailed overview of MicroPort NeuroTech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


MicroPort NeuroTech (HKSE:02172) Business Description

Traded in Other Exchanges
N/A
Address
No. 1661 Zhangdong Road, Pudong New Area, Shanghai, CHN
MicroPort NeuroTech Ltd is into the neuro-interventional medical device industry, dedicated to providing innovative solutions for physicians and patients. The company boast a comprehensive portfolio of approved therapeutic products covering all of the three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke.
Executives
Hu Yibin
Biolink Biomedical Ltd. 2201 Interest of corporation controlled by you
Blossom Vision Limited 2201 Interest of corporation controlled by you
Lion Fish Limited 2201 Interest of corporation controlled by you
Suntera Corporate Trustees (hong Kong) Limited 2301 Trustee
Thriving Hope Limited 2201 Interest of corporation controlled by you
Biolink Fund Limited Partnership 2201 Interest of corporation controlled by you
Biolink Limited 2101 Beneficial owner
Microport Scientific Corporation
Microport Scientific Investment Ltd
Maxwell Maxcare Science Foundation Limited
We'tron Capital Limited

MicroPort NeuroTech (HKSE:02172) Headlines

No Headlines